Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse

Recently, glycogen synthase kinase-3 (GSK-3) has being identified as an ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. The aim of this study was to investigate the effects o...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 120(2006), 1 vom: 18. Juli, Seite 57-67
1. Verfasser: Cuzzocrea, Salvatore (VerfasserIn)
Weitere Verfasser: Mazzon, Emanuela, Di Paola, Rosanna, Muià, Carmelo, Crisafulli, Concetta, Dugo, Laura, Collin, Marika, Britti, Domenico, Caputi, Achille P, Thiemermann, Christoph
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Retracted Publication 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione Chemokine CCL3 Chemokine CCL4 Chemokine CXCL2 Collagen Type II Interleukin-6 Macrophage Inflammatory Proteins mehr... Monokines Protein Kinase Inhibitors Thiadiazoles Tumor Necrosis Factor-alpha 3-nitrotyrosine 3604-79-3 Tyrosine 42HK56048U Nitric Oxide Synthase Type II EC 1.14.13.39 Cyclooxygenase 2 EC 1.14.99.1 Poly(ADP-ribose) Polymerases EC 2.4.2.30 Glycogen Synthase Kinase 3 beta EC 2.7.11.1 Gsk3b protein, mouse Glycogen Synthase Kinase 3 EC 2.7.11.26
Beschreibung
Zusammenfassung:Recently, glycogen synthase kinase-3 (GSK-3) has being identified as an ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. The aim of this study was to investigate the effects of GSK-3beta inhibition on the degree of arthritis caused by type II collagen (CII) in the mouse (collagen-induced arthritis; CIA). Mice developed erosive hind paw arthritis when immunized with CII in an emulsion in complete Freund's adjuvant (CFA). The incidence of CIA was 100% by day 28 in the CII-challenged mice and the severity of CIA progressed over a 35-day period with radiographic evaluation revealing focal resorption of bone. The histopathology of CIA included erosion of the cartilage at the joint margins. Treatment of mice with the GSK-3beta inhibitor TDZD-8 (1 mg/kg/day i.p.) starting at the onset of arthritis (day 25) ameliorated the clinical signs at days 26-35 and improved histological status in the joint and paw. Immunohistochemical analysis for nitrotyrosine, poly(ADP-ribose) (PAR), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) revealed a positive staining in inflamed joints from mice subjected to CIA. The degree of staining for nitrotyrosine, PAR, iNOS, and COX-2 was significantly reduced in CII-challenged mice treated with the GSK-3beta inhibitor. Plasma levels of tumor necrosis factor (TNF)-alpha and the joint tissue levels of macrophage inflammatory protein (MIP)-1alpha and MIP-2 were also significantly reduced by GSK-3beta inhibition. These data demonstrate that GSK-3beta inhibition exerts an anti-inflammatory effect during chronic inflammation and is able to ameliorate the tissue damage associated with CIA
Beschreibung:Date Completed 03.08.2006
Date Revised 12.04.2024
published: Print-Electronic
RetractionIn: Clin Immunol. 2024 May;262:110198. - PMID 38555221
Citation Status MEDLINE
ISSN:1521-7035